Work

Ruta graveolens extract induces DNA damage pathways and blocks Akt activation to inhibit cancer cell proliferation and survival.

Year: 2011

Type: article

Abstract: BACKGROUND: Ruta graveolens is a medicinal herb that has been used for centuries against various ailments. This study examined the anticancer properties of the herb using cancer cell lines. MATERIALS AND METHODS: Methanolic extract of R. graveolens was tested on colon, breast and prostate cancer cells. Viability, cell cycle profiles, clonogenicity and capase activation were measured. Induction and subcellular localizations of p53, 53BP1 and γ-H2AX proteins were examined. RESULTS: The extract dose-dependently decreased the viability and the clonogenicity of treated cells and induced G₂/M arrest, aberrant mitoses, and caspase-3 activation. It also induced the p53 pathway and focal concentration of the DNA damage response proteins 53BP1 and γ-H2AX. Moreover, the levels of phospho-Akt and cyclin B1 were reduced by treatment, whereas only cyclin B1 was reduced in normal dermal fibroblasts. CONCLUSION: R. graveolens extract contains bioactive compounds which, independently of known photoactivatable mechanisms, potently inhibit cancer cell proliferation and survival through multiple targets.

Source: PubMed

Authors: Khalda Fadlalla, Angela Watson, Teshome Yehualaeshet, Timothy Turner, Temesgen Samuel

Institution: Center for Cancer Research

Language: English

Topic: Medicinal Plant Research

Subfield: Plant Science

Field: Agricultural and Biological Sciences

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute on Minority Health and Health Disparities

Awards: Reducing Health Disparities in Alabama's Black Belt, CENTER FOR BIOMEDICAL RESEARCH, Molecular Determinants for the Bioactivity of the Flavonoid Quercetin, 2/3 Morehouse School of Medicine/Tuskegee University/ University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership, 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership